Do you want to link to this External Website and leave

YOU ARE NOW LEAVING THIS WEBSITE. Amgen Netherlands takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Biomarkers: The key to transforming lung cancer care

In the Netherlands, lung cancer is the third most common cancer with 14,176 new cases diagnosed in 2019.1 It is the main cause of cancer-related deaths (10,233 deaths in 2019)1.

Lung cancer is not "one disease": there are different types and each type of lung cancer is different. It is important to know exactly what type of lung cancer it is because to gain insights into the course of the disease and its treatment.

In order to predict whether a patient will benefit from a specific treatment, biomarker tests must be performed.

What are biomarkers?

Biomarkers are markers in cells or in the body that say something about the behavior and type of cancer. Biomarkers are used to analyze the type of cancer and which treatment has the best chance of succeeding. Thus, the use of biomarkers increases the chances of successful treatment.

What is biomarker testing in lung cancer and why is biomarker testing important?

Biomarker testing is a group of laboratory-based tests that look for naturally occurring molecules, in samples of a patient’s blood, bodily fluids or tissues.2 It tests for the occurrence of known mutations. The test results are given to clinicians so they can plan the best care for their patients. In lung cancer, biomarkers are often driver mutations which are genetic alterations that cause cells to grow out of control. Common driver mutations in lung cancer are: KRAS, EGFR, BRAF, ALK, MET, ROS-1, NTRK3

For most patients newly diagnosed with lung cancer biomarker testing is recommended. It is important to know the biomarker status to identify and decide on the most appropriate treatment.


1Longkanker Nederland. Statistieken. Available at:, Accessed July 2021
2LunGevity Foundation. Biomarker Testing. Available at:,PD%2DL1%20protein%20expression%20level. Accessed January 2021.
3ESMO. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018 [Updated September 2020]; 29 (Suppl 4): iv192–iv237. Available from:

In this section

Amgen pipelineicon

Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses.

Introduction in biotechnologyicon

Amgen was one of the first companies to recognize the potential of modern biotechnology in developing valuable medicines for patients. Today’s biologic medicines have made a significant difference to the lives of patients with serious illnesses.

Immuno-oncology: The next generation of cancer treatmenticon

The immune system is a powerful weapon against cancer. Find out here how the body’s defense mechanism is used in cancer therapy.

Clinical researchicon

One of the most important steps in the long and careful process of developing new therapies are clinical trials. These involve people volunteering to receive a new therapy and its effects being investigated.

Amgen biosimilarsicon

Biosimilars offer the potential to increase patient access to vital medicines. Amgen is well positioned to leverage its more than 40 years of experience in biotechnology to create high-quality biosimilars and reliably supply them to patients worldwide.

Biomarkers: The key to transforming lung cancer treatmenticon

Lung cancer is not "one disease": there are different types and each type of lung cancer is different. Read more why biomarker testing is recommended.